Nu Skin Enterprises Reports First-Quarter 2020 Results
Executive Summary |
|
Revenue: |
· (2%) fx impact or |
Earnings Per Share (EPS): |
|
Sales Leaders: |
49,551; (22%) |
Customers: |
1,130,947; (5%) |
"The efforts and resiliency of our sales leaders and global teams helped us achieve revenue and earnings above guidance in the first quarter," said
"Our first quarter results demonstrated continued stability in the
Q1 2020 Year-Over-Year Operating Results |
|
Revenue: |
· (2%) fx impact or |
Gross Margin: |
75.7% compared to 76.5% · |
Selling Expenses: |
39.8% of revenue compared to 40.0% · |
G&A Expenses: |
28.9% of revenue compared to 25.4% |
Operating Margin: |
7.1% compared to 11.0% |
Other Income / (Expense): |
· |
Income Tax Rate: |
35.1% compared to 34.7% |
EPS: |
|
Stockholder Value |
|
Dividend Payments: |
|
Stock Repurchases: |
· 409.3 million remaining in authorization |
Q2 and Full-Year 2020 Outlook |
|
Q2 2020 Revenue: |
· Approximately (3 to 4%) fx impact |
Q2 2020 EPS: |
|
2020 Revenue: |
· Approximately (2 to 3%) fx impact |
2020 EPS |
|
"While there is a great deal of uncertainty in the broader economy, we are optimistic our business will perform well as sales leaders leverage our technology investments to drive product demand and interest in the business opportunity," said Wood. "The situation in Mainland China is stabilizing with the country returning to work, a key development we believe will translate into improvement throughout the year. We anticipate similar trends in most of our other markets as pandemic restrictions begin to ease elsewhere across the globe. We continue to believe this trend, paired with the global preview of our newest beauty device late in 2020, sets our business up for a return to growth toward the end of the year," Wood concluded.
Conference Call
The
About
Founded 35 years ago,
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, growth, product launches, benefits to shareholders, strategies and initiatives; statements of management's expectations regarding the future status of the COVID-19 pandemic globally and across the company's markets, and government and public behavior in response to such status; projections regarding revenue, earnings per share, foreign currency fluctuations and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "continue," "anticipate," "optimistic," "benefit," "project," "outlook," "guidance," "plan," "continue," "will," "would," "could," "may," "might," the negative of these words and other similar words.
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
- risk that epidemics, including the recent outbreak of coronavirus, and other crises could negatively impact our business;
- adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
- risk that direct selling laws and regulations in any of the company's markets, including
the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company's business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse actions or events; - any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
- uncertainty regarding the continued impact of the 100-day review and negative media and consumer sentiment in Mainland China on our business operations and results;
- risk of foreign-currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
- uncertainties regarding the future financial performance of the businesses the company has acquired;
- risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
- regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;
- unpredictable economic conditions and events globally, including trade policies and tariffs;
- uncertainties related to interpretation of, and forthcoming regulations under, the recently enacted
U.S. tax reform legislation; the company's future tax-planning initiatives; any prospective or retrospective increases in duties on the company's products imported into the company's markets outside ofthe United States ; and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and - continued competitive pressures in the company's markets.
The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the
Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period's revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company's revenue from period to period.
The Company's revenue results by segment for the three-month periods ended
Three Months Ended |
Constant- |
||||||||||
2020 |
2019 |
Change |
Change |
||||||||
|
|||||||||||
Mainland |
$ |
137,696 |
$ |
208,488 |
(34)% |
(31)% |
|||||
|
75,719 |
83,853 |
(10)% |
(4)% |
|||||||
|
74,573 |
86,456 |
(14)% |
(9)% |
|||||||
|
69,586 |
72,495 |
(4)% |
(3)% |
|||||||
|
61,300 |
62,109 |
(1)% |
(2)% |
|||||||
|
35,827 |
40,558 |
(12)% |
(13)% |
|||||||
EMEA |
35,403 |
41,818 |
(15)% |
(13)% |
|||||||
Other |
773 |
(1,426) |
154% |
154% |
|||||||
Total |
490,877 |
594,351 |
(17)% |
(15)% |
|||||||
Manufacturing |
27,147 |
29,272 |
(7)% |
(7)% |
|||||||
Grow Tech |
4 |
— |
— |
— |
|||||||
Total |
$ |
518,028 |
$ |
623,623 |
(17)% |
(15)% |
The company's Customers and Sales Leaders statistics by segment for the three-month periods ended
As of |
As of |
% Increase (Decrease) |
|||||||||||||||
Customers |
Sales Leaders |
Customers |
Sales Leaders |
Customers |
Sales Leaders |
||||||||||||
Mainland |
271,536 |
16,159 |
272,053 |
26,986 |
— |
(40)% |
|||||||||||
|
174,004 |
6,608 |
181,150 |
6,671 |
(4)% |
(1)% |
|||||||||||
|
214,139 |
6,930 |
242,925 |
7,862 |
(12)% |
(12)% |
|||||||||||
|
145,116 |
6,634 |
138,112 |
7,071 |
5% |
(6)% |
|||||||||||
|
119,784 |
5,635 |
126,526 |
5,840 |
(5)% |
(4)% |
|||||||||||
|
66,024 |
3,348 |
70,354 |
3,959 |
(6)% |
(15)% |
|||||||||||
EMEA |
140,344 |
4,237 |
162,086 |
4,859 |
(13)% |
(13)% |
|||||||||||
Total |
1,130,947 |
49,551 |
1,193,206 |
63,248 |
(5)% |
(22)% |
|
|||||
Consolidated Statements of Income (Unaudited) |
|||||
( |
|||||
Three Months Ended |
|||||
2020 |
2019 |
||||
Revenue |
$ |
518,028 |
$ |
623,623 |
|
Cost of sales |
125,793 |
146,664 |
|||
Gross profit |
392,235 |
476,959 |
|||
Operating expenses: |
|||||
Selling expenses |
206,042 |
249,708 |
|||
General and administrative expenses |
149,628 |
158,598 |
|||
Total operating expenses |
355,670 |
408,306 |
|||
Operating income |
36,565 |
68,653 |
|||
Other income (expense), net |
(6,174) |
(2,848) |
|||
Income before provision for income taxes |
30,391 |
65,805 |
|||
Provision for income taxes |
10,661 |
22,803 |
|||
Net income |
$ |
19,730 |
$ |
43,002 |
|
Net income per share: |
|||||
Basic |
$ |
0.36 |
$ |
0.78 |
|
Diluted |
$ |
0.36 |
$ |
0.77 |
|
Weighted-average common shares outstanding (000s): |
|||||
Basic |
55,059 |
55,436 |
|||
Diluted |
55,101 |
56,128 |
|
|||||
Consolidated Balance Sheets (Unaudited) |
|||||
( |
|||||
|
|
||||
ASSETS |
|||||
Current assets: |
|||||
Cash and cash equivalents |
$ |
352,578 |
$ |
335,630 |
|
Current investments |
9,087 |
8,413 |
|||
Accounts receivable |
43,973 |
50,378 |
|||
Inventories, net |
257,474 |
275,891 |
|||
Prepaid expenses and other |
66,457 |
69,854 |
|||
Total current assets |
729,569 |
740,166 |
|||
Property and equipment, net |
449,486 |
453,604 |
|||
Right-of-use assets |
147,678 |
144,326 |
|||
|
196,573 |
196,573 |
|||
Other intangible assets, net |
77,796 |
80,321 |
|||
Other assets |
145,217 |
154,016 |
|||
Total assets |
$ |
1,746,319 |
$ |
1,769,006 |
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||||
Current liabilities: |
|||||
Accounts payable |
$ |
39,891 |
$ |
38,979 |
|
Accrued expenses |
285,213 |
290,281 |
|||
Current portion of long-term debt |
95,000 |
27,500 |
|||
Total current liabilities |
420,104 |
356,760 |
|||
Operating lease liabilities |
108,145 |
105,701 |
|||
Long-term debt |
327,197 |
334,461 |
|||
Other liabilities |
90,375 |
96,795 |
|||
Total liabilities |
945,821 |
893,717 |
|||
Stockholders' equity: |
|||||
Class A common stock |
91 |
91 |
|||
Additional paid-in capital |
557,916 |
557,544 |
|||
|
(1,384,036) |
(1,324,826) |
|||
Accumulated other comprehensive loss |
(100,289) |
(85,292) |
|||
Retained earnings |
1,726,816 |
1,727,772 |
|||
Total stockholders' equity |
800,498 |
875,289 |
|||
Total liabilities and stockholders' equity |
$ |
1,746,319 |
$ |
1,769,006 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/nu-skin-enterprises-reports-first-quarter-2020-results-301054241.html
SOURCE
Media: media@nuskin.com, (801) 345-6397 or Investors: investorrelations@nuskin.com, (801) 345-3577